AtriCure (ATRC) Cash & Equivalents (2010 - 2026)

AtriCure (ATRC) has 17 years of Cash & Equivalents data on file, last reported at $146.2 million in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $146.2 million, up 46.33% year-over-year; the trailing twelve-month figure through Mar 2026 was $146.2 million (up 46.33% YoY), and the FY2025 annual result was $167.4 million, up 36.43% from the prior year.
• Cash & Equivalents slipped to $146.2 million in Q1 2026 per ATRC's latest filing, from $167.4 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $167.4 million in Q4 2025 and troughed at $28.1 million in Q1 2022.
• A 5-year average of $94.3 million and a median of $84.3 million in 2023 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2022 and 2023: Cash & Equivalents tumbled 67.04% in 2022, then jumped 174.83% in 2023.
• A 5-year view of Cash & Equivalents shows it stood at $58.1 million in 2022, then surged by 45.11% to $84.3 million in 2023, then surged by 45.56% to $122.7 million in 2024, then surged by 36.43% to $167.4 million in 2025, then retreated by 12.7% to $146.2 million in 2026.
• Business Quant data shows ATRC's Cash & Equivalents at $146.2 million in Q1 2026, $167.4 million in Q4 2025, and $147.9 million in Q3 2025.